Sign In
Buy DNLI
$19.66
+0.310 (+1.60%)
At Close: Jun 03, 2026
Aimmune's Palforzia Wins FDA Approval for Peanut Allergy
04:11pm, Monday, 03'rd Feb 2020
Aimmune's (AIMT) Palforzia is the first medicine to receive an FDA nod for treating patients with peanut allergy. Shares rise in pre-market trading.
Denali Therapeutics (NASDAQ:DNLI) Downgraded to Hold at ValuEngine
10:48am, Saturday, 01'st Feb 2020
ValuEngine downgraded shares of Denali Therapeutics (NASDAQ:DNLI) from a buy rating to a hold rating in a research report released on Tuesday morning, ValuEngine reports. A number of other equities re
Head to Head Analysis: Denali Therapeutics (NASDAQ:DNLI) & Amgen (NASDAQ:AMGN)
06:22am, Saturday, 01'st Feb 2020
Denali Therapeutics (NASDAQ:DNLI) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitabilit
Denali Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
01:42am, Saturday, 01'st Feb 2020
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing of its upsized underwritten public offering of 9,000,000.
Denali Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
01:41am, Saturday, 01'st Feb 2020
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing of its upsized...
Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales
08:02pm, Friday, 31'st Jan 2020
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales
08:02pm, Friday, 31'st Jan 2020
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
Moving Average Crossover Alert: Denali Therapeutics
02:52pm, Friday, 31'st Jan 2020
Denali Therapeutics Inc. (DNLI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Moving Average Crossover Alert: Denali Therapeutics
02:52pm, Friday, 31'st Jan 2020
Denali Therapeutics Inc. (DNLI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Intercept (ICPT) Concludes Enrollment in Study on NASH Drug
04:10pm, Thursday, 30'th Jan 2020
Intercept (ICPT) closes enrollment in late-stage study evaluating obeticholic acid for the treatment of compensated cirrhosis due to nonalcoholic steatohepatitis.
Goldman Sachs: These 2 Stocks Are Poised to Surge by at Least 35%
03:54pm, Thursday, 30'th Jan 2020
Once again, the world is gripped by uncertainty. Fear of an international outbreak of coronavirus, on top of recent worrisome developments between the US and Iran, have spooked investors, sending all
Alexion (ALXN) Q4 Earnings Beat Estimates, Revenues Up Y/Y
03:15pm, Thursday, 30'th Jan 2020
Alexion (ALXN) beats on earnings and revenues in the fourth quarter of 2019.
Alexion (ALXN) Q4 Earnings Beat Estimates, Revenues Up Y/Y
03:15pm, Thursday, 30'th Jan 2020
Alexion (ALXN) beats on earnings and revenues in the fourth quarter of 2019.
Incyte's Phase III Atopic Dermatitis Study Meets Primary Goal
04:11pm, Wednesday, 29'th Jan 2020
Incyte (INCY) posts positive top-line results from late-stage TRuE-AD2 study on ruxolitinib cream to treat adolescent and adult patients with atopic dermatitis. The study achieves its main goal.
Gilead's Mantle Cell Lymphoma Drug MAA Gets EMA Validation
03:06pm, Wednesday, 29'th Jan 2020
Gilead's (GILD) Marketing Authorization Application for KTE-X19 has been fully validated and is now under evaluation with the EMA.
